Google, Twitter, Yahoo Nab HealthCare.gov Data

Companies including Google, Twitter, Yahoo and Advertising.com automatically obtain information from people visiting HealthCare.gov, according to analysis by congressional staffers.

The finding builds on news last week that dozens of data-tracking companies were able to obtain information about people visiting the federal healthcare website, potentially including information about their age, location, and pregnancy status.

After The Associated Press revealed details about that sharing of data on January 20, staffers performed analysis of their own, which only increased concern from leading congressional Republicans.

Read more at The Hill: http://bit.ly/1zLjop2

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Atopic Dermatitis Itch. | Image Credit: Pormezz - stock.adobe.com .jpeg

July 1st 2025

Top Risk Factors for Anxiety, Depression Identified in Atopic Dermatitis

Pearl Steinzor

This new study identifies key contributors to mental health decline in individuals with atopic dermatitis, highlighting the need for integrated care.

June 24th 2025

Addressing the Physical, Psychological Complexity of IBD Through Coordinated Care

Giuliana Grossi Skylar Jeremias Eva Szigethy, MD, PhD Benjamin Cohen, MD

Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by integrating mental health support and addressing stigma.

Joshua K. Sabari, MD | Image: NYU Langone

Published: July 1st 2025 | Updated: June 30th 2025

PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity

Joshua K. Sabari, MD Interview by Mary Caffrey

Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine kinase inhibitor offers high response rates and improved quality of life with minimal toxicity.

June 19th 2025

Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays

Maggie L. Shaw Colin Banas, MD, MHA

Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.

SRP-9003 is currently being evaluated in a phase 1/2 clinical trial and the phase 3 EMERGENE clinical trial. | Image credit: vladimircaribb - stock.adobe.com

July 1st 2025

FDA Grants Platform Technology Designation to Limb-Girdle Muscular Dystrophy Gene Therapy Vector

Noah Stansfield

The platform technology designation is a new designation established by the FDA.

$Patients with RS-negative low-risk MDS who were relapsed or refractory to or ineligible for ESAs appeared to experience clinical benefit with imetelstat treatment in a post hoc analysis. | Image credit: fotogurmespb - stock.adobe.com$

July 1st 2025

Imetelstat Shows Benefit in RS-Negative, Lower-Risk MDS

Ashley Chan

Imetelstat demonstrated clinical benefits in patients with ring sideroblast–negative lower-risk MDS, according to a post hoc analysis.

Related Content

July 1st 2025

Top Risk Factors for Anxiety, Depression Identified in Atopic Dermatitis

Pearl Steinzor

This new study identifies key contributors to mental health decline in individuals with atopic dermatitis, highlighting the need for integrated care.

June 24th 2025

Addressing the Physical, Psychological Complexity of IBD Through Coordinated Care

Giuliana Grossi Skylar Jeremias Eva Szigethy, MD, PhD Benjamin Cohen, MD